# US 2019/0167619 A1 · Pharmaceutical formulations and their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167619 A1
- Document ID: US20190167619A1
- Status: Published application
- Kind: A1
- Application number: 16/323,970
- Filed: 2017-08-08
- Published: 2019-06-06
- Earliest claimed: 2016-08-08
- Assignees: Signum Biosciences, Inc.
- Applicants: Signum Biosciences, Inc.
- Inventors: Michael VORONKOV; Gareth WINCKLE
- Web page: https://patentgrep.com/patent/US20190167619A1

## CPC

- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61P 17/00: Drugs for dermatological disorders
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61P 17/10: Anti-acne agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition comprising (a) at least one protective agent selected from the group consisting of butylated hydroxyanisole, butylated hydroxytoluene, sodium metabisulfite, tert-butylhydroquinone, methylparaben, propylparaben, benzyl alcohol, poly(acrylic acid), hydroxyethyl cellulose, emulsifying wax, PEG-21 stearyl ether, PEG-2 stearyl ether, white petrolatum, myristyl lactate, diisopropyl adipate, cetyl alcohol, cyclomethicone, oleyl alcohol, cholesterol, and polyoxyethylene(4)lauryl ether; and (b) a therapeutically effective amount of an IPC Active Agent or a pharmaceutically acceptable salt or ester thereof.

## Claims

### Claim 1

A pharmaceutical composition comprising (a) at least one protective agent selected from the group consisting of butylated hydroxyanisole, butylated hydroxytoluene, sodium metabisulfite, tert-butylhydroquinone, methylparaben, propylparaben, benzyl alcohol, poly(acrylic acid), hydroxyethyl cellulose, emulsifying wax, PEG-21 stearyl ether, PEG-2 stearyl ether, white petrolatum, myristyl lactate, diisopropyl adipate, cetyl alcohol, cyclomethicone, oleyl alcohol, cholesterol, and polyoxyethylene(4)lauryl ether; and (b) a therapeutically effective amount of an IPC Active Agent or a pharmaceutically acceptable salt or ester thereof.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the protective agent is selected from the group consisting of butylated hydroxyanisole, butylated hydroxytoluene, sodium metabisulfite, tert-butylhydroquinone, methylparaben, propylparaben, and poly(acrylic acid).

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the protective agent includes butylated hydroxyanisole.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the butylated hydroxyanisole is present in an amount from about 0.001% to about 2%, based on the total weight of the composition.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the butylated hydroxyanisole is present in an amount from about 0.005% to about 1%, based on the total weight of the composition.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the protective agent includes sodium metabisulfite.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the sodium metabisulfite is present in an amount from about 0.01% to about 5%, based on the total weight of the composition.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the butylated hydroxyanisole is present in an amount from about 0.05% to about 1%, based on the total weight of the composition.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the protective agent includes tert-butylhydroquinone.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the tert-butylhydroquinone is present in an amount from about 0.001% to about 2%, based on the total weight of the composition.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10, wherein the tert-butylhydroquinone is present in an amount from about 0.005% to about 1%, based on the total weight of the composition.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes a compound depicted by Formula I:
wherein:
L is a bivalent, branched or unbranched, saturated or unsaturated, C2-C6 hydrocarbon chain wherein one or more methylene units of L is independently replaced by —O—, —S—, —NH—, —C(O)—, —C═CH2—, or C3-C6 cycloalkylene, wherein L is optionally substituted by one or more groups selected from halogen, phenyl, an 8-10 membered bicyclic aryl ring, a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5- to 7-membered monocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur or a 7-10 membered bicyclic heterocyclyl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R1 is hydrogen, —OH or —OR, wherein each R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic or C1-6 heteroaliphatic;
R2 is —C(O)X, wherein X is independently R, —OR, a hydrogen, aryloxy, amino, alkylamino, dialkylamino, heteroaryloxy, hydrazine, a 6-10 membered aryl ring, a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein each R is independently hydrogen or an optionally substituted group selected from C1-6 aliphatic or C1-6 heteroaliphatic; and
R3 is a substituted or unsubstituted, branched or unbranched, saturated or unsaturated, C10-C25 aliphatic,
or a pharmaceutically acceptable salt or ester thereof.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes 4-((1-carboxy-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)ethyl)amino)-4-oxobutanoic acid or a pharmaceutically acceptable salt or ester thereof.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes the disodium salt of 4-((1-carboxy-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)ethyl)amino)-4-oxobutanoic acid.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes 4-(((R)-1-carboxy-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)ethyl)amino)-4-oxobutanoic acid, or a pharmaceutically acceptable salt or ester thereof.

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes the disodium salt of 4-(((R)-1-carboxy-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)ethyl)amino)-4-oxobutanoic acid.

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes 4-(((S)-1-carboxy-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)ethyl)amino)-4-oxobutanoic acid, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes the disodium salt of 4-(((S)-1-carboxy-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)ethyl)amino)-4-oxobutanoic acid, or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes at least 75 wt % of 4-(((R)-1-carboxy-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)ethyl)amino)-4-oxobutanoic acid, or pharmaceutically acceptable salt or ester thereof, based on the total weight of 4-((1-carboxy-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-thio)ethyl)amino)-4-oxobutanoic acid or a pharmaceutically acceptable salt or ester thereof present in the composition.

### Claim at position 20

20-21. (canceled)

### Claim 22 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes at least 90 wt % of 4-(((R)-1-carboxy-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)ethyl)amino)-4-oxobutanoic acid, or pharmaceutically acceptable salt or ester thereof, based on the total weight of 4-((1-carboxy-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-thio)ethyl)amino)-4-oxobutanoic acid or a pharmaceutically acceptable salt or ester thereof present in the composition.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes at least 97.5 wt % of 4-(((R)-1-carboxy-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)ethyl)amino)-4-oxobutanoic acid, or pharmaceutically acceptable salt or ester thereof, based on the total weight of 4-((1-carboxy-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-thio)ethyl)amino)-4-oxobutanoic acid or a pharmaceutically acceptable salt or ester thereof present in the composition.

### Claim 25 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes:
or a pharmaceutically acceptable salt or ester thereof.

### Claim 26 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes at least 75 wt % of:
or pharmaceutically acceptable salt or ester thereof, based on the total weight of (E)-4-((1-carboxy-2-((3,7,11,15-tetramethylhexadec-2-en-1-yl)thio)ethyl)amino)-4-oxobutanoic acid or a pharmaceutically acceptable salt or ester thereof present in the composition.

### Claim at position 26

27-28. (canceled)

### Claim 29 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes at least 90 wt % of
or pharmaceutically acceptable salt or ester thereof, based on the total weight of (E)-4-((1-carboxy-2-((3,7,11,15-tetramethylhexadec-2-en-1-yl)thio)ethyl)amino)-4-oxobutanoic acid or a pharmaceutically acceptable salt or ester thereof present in the composition.

### Claim 30

(canceled)

### Claim 31 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes at least 97.5 wt % of
or pharmaceutically acceptable salt or ester thereof, based on the total weight of (E)-4-((1-carboxy-2-((3,7,11,15-tetramethylhexadec-2-en-1-yl)thio)ethyl)amino)-4-oxobutanoic acid or a pharmaceutically acceptable salt or ester thereof present in the composition.

### Claim 32 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes:
or a pharmaceutically acceptable salt or ester thereof.

### Claim 33 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes at least 75 wt % of:
or pharmaceutically acceptable salt or ester thereof, based on the total weight of N-(acetylglutaminyl)-S-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)cysteine or a pharmaceutically acceptable salt or ester thereof present in the composition.

### Claim at position 32

34-35. (canceled)

### Claim 36 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes at least 90 wt % of:
or pharmaceutically acceptable salt or ester thereof, based on the total weight of N-(acetylglutaminyl)-S-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)cysteine or a pharmaceutically acceptable salt or ester thereof present in the composition.

### Claim 37

(canceled)

### Claim 38 (depends on 1)

The pharmaceutical composition of claim 1, wherein the IPC Active Agent includes at least 97.5 wt % of:
or pharmaceutically acceptable salt or ester thereof, based on the total weight of N-(acetylglutaminyl)-S-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)cysteine or a pharmaceutically acceptable salt or ester thereof present in the composition.
